Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma (NCT07708961)

🧪 Interventions in This Study

• EGFR/EGFRvIII Inhibitor WSD0922-FU (DRUG)
• Temozolomide (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Age \>= 18 years
2. Histopathologic diagnosis of glioblastoma, IDH-wildtype \[as defined by the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors\] on primary pathology review
3. NOTE: MGMT promoter methylation status must have been performed
4. Glioblastomas must have a pathogenic EGFR mutation, with or without EGFR amplification, detected by Clinical Laboratory Improvement Act (CLIA)-certified next-generation sequencing
5. EGFR mutation includes both deoxyribonucleic acid (DNA) sequence variants (e.g. point mutations, etc.) and transcript variants (e.g. EGFRvIII, etc.)
6. EXCEPTIONS: Glioblastomas which are EGFR wildtype with amplification are excluded. Glioblastomas which only have EGFR variants of unknown significance (without any pathogenic EGFR mutations) are also excluded
7. Patients must have completed standard radiation (60 Gy in 30 fractions) with concurrent temozolomide (missing no more than 2 weeks of temozolomide), and adequately recovered from treatment related toxicities
8. NOTE: Adjuvant temozolomide must not have been initiated
9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
10. Hemoglobin \> 9.0 g/dL (obtained =\< 14 days prior to registration)
11. Leukocytes \> 3.0 x 10\^9/L (obtained =\< 14 days prior to registration)
12. Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L (obtained =\< 14 days prior to registration)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

• Mayo Clinic in Arizona — Scottsdale, Arizona
• Mayo Clinic in Florida — Jacksonville, Florida
• Mayo Clinic in Rochester — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Email: mayocliniccancerstudies@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma, IDH-Wildtype

• Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma — Birmingham, Alabama
• The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma — San Francisco, California
• Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma — Phoenix, Arizona
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma — Rochester, Minnesota
• WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma — Chicago, Illinois

Explore by condition: All Glioblastoma, IDH-Wildtype clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.